How many drugs treat Chlamydia Cervicitis?

Drug Landscape tracks 7 marketed treatments for Chlamydia Cervicitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chlamydia-cervicitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chlamydia Cervicitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chlamydia Cervicitis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chlamydia Cervicitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Azo Gantrisin	sulfafurazole	Alra	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01
E-Mycin	erythromycin	Generic (originally Abbott/Lilly)	Macrolide [EPC]	Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1	1952-01-01
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Chlamydia Cervicitis
· 2 drugs in Chlamydia Cervicitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Chlamydia Cervicitis
Otsuka · 1 drug in Chlamydia Cervicitis
Pfizer Inc. · 1 drug in Chlamydia Cervicitis
Generic (originally Abbott/Lilly) · 1 drug in Chlamydia Cervicitis
Alra · 1 drug in Chlamydia Cervicitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chlamydia Cervicitis:

Cite this brief

Drug Landscape (2026). Chlamydia Cervicitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chlamydia-cervicitis. Accessed 2026-06-10.

Chlamydia Cervicitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing